{"id":66119,"date":"2026-04-22T13:45:21","date_gmt":"2026-04-22T13:45:21","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/66119\/"},"modified":"2026-04-22T13:45:21","modified_gmt":"2026-04-22T13:45:21","slug":"softox-solutions-as-new-share-capital","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/66119\/","title":{"rendered":"SoftOx Solutions AS: New Share Capital"},"content":{"rendered":"<p>Reference is made to the stock exchange release from SoftOx Solutions AS (the<br \/>&#8220;Company&#8221;) on 13 April 2026 regarding the board resolution to increase the share<br \/>capital by carrying out a private placement of NOK 7 200 000 under the financing<br \/>facility with the investment fund Long State Investments Limited (&#8220;Long State&#8221;).<\/p>\n<p>The new share capital following completion of the private placement has today<br \/>been registered with the Norwegian Register of Business Enterprises.  <\/p>\n<p>The new share capital of the Company is NOK 51 108 339.88 divided into 2 555 416<br \/>994 shares, each with a par value of NOK 0.02. <\/p>\n<p>For more information on the financing facility, please see the Company&#8217;s stock<br \/>exchange release dated 14 September 2025. <\/p>\n<p>For further information, please contact:  <\/p>\n<p>Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87  <br \/>Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165  <br \/>Mail: ir@soft-ox.com  <\/p>\n<p>About SoftOx Solutions AS:<br \/>SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company<br \/>listed on Euronext Growth Oslo. The company is developing highly effective<br \/>pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The<br \/>technology is based on extensive research and development in partnership with<br \/>leading Nordic research institutes. <\/p>\n","protected":false},"excerpt":{"rendered":"Reference is made to the stock exchange release from SoftOx Solutions AS (the&#8220;Company&#8221;) on 13 April 2026 regarding&hellip;\n","protected":false},"author":2,"featured_media":52867,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[85],"tags":[31683,31684,36360,157,156,2255],"class_list":["post-66119","post","type-post","status-publish","format-standard","has-post-thumbnail","category-oslo","tag-moichc","tag-moichc20","tag-moichc2030","tag-norway","tag-oslo","tag-regulatory"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116448665864821858","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/66119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=66119"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/66119\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/52867"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=66119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=66119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=66119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}